London and San Francisco venture firm founded in 2025 by Ali Mitchell and Michelle Robson. Its Discovery strategy backs European pre-seed and seed companies; Access supports global Series B and later growth companies. The current portfolio includes neural-interface company Axo Neurotech and neural-implant semiconductor company MintNeuro, with investment dates and checks undisclosed. Founder history and investments at earlier firms require separate attribution.
Founded 2025
Type Venture capital 2 Odyssey Discovery I 2026-07-23 2026-07-23 — USD50M intended fullfund, 50% closed at2026-07-23. Explicit monetary closedamount not separatelyreported; no inferredUSD25M verifiedamount stored. GBP10M RegionalAngelsalongsidecommitment separate; USD87M combinedAUM notindividualfund. Postsummerfinalclose unverified.
Odyssey Ventures Access (Growth) I — — GlobalSeriesB+ growthstrategy; PEIvehiclelisting confirmsinmarket. Target/close/vintage unverified; no arithmeticdecomposition ofUSD87MAUM.
SHOW MORE
$100K $10K – $500K San Francisco Bay Area $0 $0 – $0 — — – — — — – —
SHOW MORE
team@apexlogos.ai · 10 hours ago
Investment-fund research reviewed 2026-10-06. Publicly identified funds, dates, amounts and fundraising status are below. Undisclosed commitments remain unknown; this is not a complete register of private SPVs or parallel entities.
Fund size, vintages and closing status
| Vehicle / metric | Latest dated evidence found | Interpretation |
| --- | --- | --- |
| Odyssey Discovery I | British Business Bank, 2026-07-23: **US$50 million** pre-seed/seed fund, **50% closed**, aiming for final close after summer | Treat $50m as announced intended full fund size; do not record a verified $50m final close. No later final-close confirmation found in the checked sources. |
| British Business Bank Regional Angels Programme | Same announcement: **£10 million commitment to invest alongside** the early-stage fund | Separate co-investment commitment; not automatically part of fund commitments or deployable closed fund total. |
| Total firm AUM | Same announcement: **US$87 million** across Access (AI global growth) and Discovery (AI/deep-tech UK-to-US early stage) | Combined AUM, not one fund. No supported vehicle-by-vehicle decomposition; do not subtract the fund target from AUM to infer Access size. |
| 2025 launch reporting | 2025-10-15 Tech Funding News reports **US$75 million** debut fund; 2025-11-02 founder interview introduces a $75m debut fund | Historical reported figure conflicts with the newer $50m Discovery description. Target, vehicle perimeter or fundraising plans may have changed, but sources do not resolve it. Not verified as final closed commitments. |
| Access growth strategy | Official site confirms global growth platform; PEI publicly lists “Odyssey Ventures Access (Growth) I” in market | Numerical target/close/vintage unverified. PEI's sizes are paywalled. |
Primary fund evidence: [British Business Bank announcement, 2026-07-23](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-commits-ps10m-odyssey-ventures-back-uks-boldest-ai-and-deeptech-founders ). Historical context: [Tech Funding News, 2025-10-15](https://techfundingnews.com/odyssey-ventures-75m-fund-bridges-europe-us-startup-valuation-gap/ ); [Ali Mitchell interview, 2025-11-02](https://sundaycet.com/2025/11/02/ali-mitchell-odyssey-ventures-the-reality-is-that-most-european-vcs-are-generalists-run-by-non-founders/ ); [PEI profile](https://www.privateequityinternational.com/institution-profiles/odyssey-ventures.html ) (undated, accessed 2026-10-06; Fund I open date September 2025, amounts inaccessible). All amounts preserve original currency. No verified firm check range found.
Funds recorded in Adex after this review:
| Fund | Disclosed amount | Announcement / filing date |
| --- | --- | --- |
| Odyssey Ventures Access (Growth) I | Undisclosed / unverified | Unknown |
| Odyssey Discovery I | Undisclosed / unverified | 2026-07-23 | SHOW MORE
team@apexlogos.ai · 11 hours ago
Match research 2026-10-06 / OdysseyVentures / sha256:284d31152326df7768e597510e0ed9d54099a58af2020c1d57fed2033ed7250c / part 2 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
| **Potential Sciences** | Older [portfolio page](https://www.odyssey.ventures/portfolio ) describes quantum chemistry plus AI for molecule design; scientific computing/drug-discovery enabling technology, conditional on that firm description. | Official current homepage explicitly lists early-stage portfolio status. [Company site](https://potentialsciences.com/ ) gives only a general scientific-discovery slogan. Specific technical architecture, transaction date, round and amount not independently verified; retain as firm-claimed scientific investment, not confirmed quantum hardware or neurotech. |
Undated official pages above accessed 2026-10-06. Flow's announcement provides round amount, not Odyssey's check. Current portfolio claims are stronger than old mixed track-record lists but still do not establish each purchase date or legal holding vehicle.
Other snapshot deep-tech leads requiring attribution review: **Heart Aerospace** (electric aircraft), **Aether Fuels** (sustainable fuels), **Amogy** (ammonia energy), **Oden Technologies** (industrial AI), **Standard AI** (computer vision), **Untap Health** (wastewater sensing). The older page includes them among “Select other investments,” while current partner biographies explicitly describe investments made at EQT and AP Ventures. They were not verified as new Odyssey fund transactions in this pass. Pleo, Peakon, AnyDesk, Beamery, Permutive, Handshake and Nodals AI are not automatically deep tech merely because they use software or AI. General.Bio is newly visible on the homepage (engineered microbes/medicines) but detailed technical and round verification is incomplete; do not invent an investment date.
## Named neurotech investments
**Axo Neurotech — verified official firm portfolio claim, with independent technical corroboration.** [Odyssey homepage](https://odyssey.ventures/ ) places it in Early-Stage. [Axo's own site](https://axoneurotech.com/ ) says it is in stealth in Palo Alto. [King's College company profile](https://www.kings.cam.ac.uk/axo-neurotech ) describes cell-based biohybrid interfaces, seven patents, pre-seed raising and investors including co-founders of Neuralink and Science Corp; none of those facts proves that those companies invested. [Cambridge Engineering, 2025-10-08](https://www.eng.cam.ac.uk/news/engineering-alumni-and-student-among-winners-king-s-college-entrepreneurship-prize ) verifies neural-interface technology and a **£20,000 entrepreneurship prize**. This is non-dilutive support, not Odyssey's equity investment. Odyssey investment date/check/round remain undisclosed.
**MintNeuro — verified official firm portfolio claim, with independently supported neural-chip technology.** [Odyssey detail](https://odyssey.ventures/companies/mintneuro ) names the company in its current early-stage fund and Empirical as co-investor. [MintNeuro website](https://mintneuro.com/ ) explains chips for neural sensing, stimulation and processing (search-index readable; direct fetch failed during this pass). [Investee funding release, 2024-11-12](https://www.prnewswire.com/news-releases/mintneuro-secures-1m-investment-to-advance-transformative-semiconductor-technology-for-neural-implants-302301650.html ) reports **£1m** led by Empirical, with Parkwalk/Imperial, Plug & Play, Excellis and angels. **It does not name Odyssey and predates the new firm's founding.** Do not assign Odyssey to that round solely because Empirical appears on its current detail page. Current Odyssey investment date and amount remain unknown. Neural implant electronics qualify as direct neurotechnology, not merely adjacent mental-health software.
No additional directly verified neurotech investment found in the sources checked. Potential Sciences' drug discovery is adjacent scientific technology and is not established as neuroscience-specific. Cameron's Signal angel portfolio is excluded from this firm's neurotech/deep-tech track record.
## Conflicts, gaps and concrete Adex review notes
1. Review/remove or reattribute Oliver Cameron roles and Signal association after confirming identity; official firm team evidence supports Mitchell/Robson, while Cameron leads a separately founded AI startup. Do not import his check sizes or angel investments.
2. Use the July 2026 Bank disclosure as latest-known dated fund evidence: Discovery intended $50m, half closed at that date; $87m combined AUM; £10m alongside-fund commitment. Resolve historical $75m reporting and seek actual final-close announcement before setting closed fund size.
3. Retain Axo and consider adding MintNeuro as explicit current neurotech portfolio claims, with investment dates/checks left unknown. Do not use Axo's prize or MintNeuro's 2024 financing as Odyssey transactions.
4. Review all 17 old portfolio participations against partner history. “Select other investments” and “we led” wording can refer to prior-firm track records; Viridi's seed demonstrates the issue concretely.
5. Flow's 2026-09-30 Series B has company-level investor confirmation; firm news supports its Series A participation separately. No unsupported lead flag or inferred check.
6. Check newly visible MintNeuro and General.Bio, and any current vehicle allocation changes. Official legacy www portfolio and current non-www homepage differ; current Flow classification is Global Growth while legacy placement was early stage.
7. Most official portfolio details lack publication dates, financing dates and amounts. No full audited holdings list, firm-wide check range, Access size or post-summer Discovery close found. Research completion means these limitations are documented, not that missing details were filled.
All URLs were checked/accessed 2026-10-06. Publication dates are supplied when supported; undated sources are explicitly treated as current page claims. Research only: no Adex/database changes made. SHOW MORE
team@apexlogos.ai · 11 hours ago
Match research 2026-10-06 / OdysseyVentures / sha256:284d31152326df7768e597510e0ed9d54099a58af2020c1d57fed2033ed7250c / part 1 of 2
Imported completed research. Baseline Adex/Signal statements describe prior state, not independent verification. Retain cited attribution, date, currency and classification caveats.
# Odyssey Ventures
- **Exact ID:** `OdysseyVentures`
- **Adex webpage:** https://adex.page/firms/OdysseyVentures
- **Research date:** 2026-10-06
- **Status:** Complete research pass; material attribution and fund-size discrepancies remain explicitly unresolved.
## Identity and conclusion
This is the London-headquartered, San Francisco-office venture firm founded in 2025 by Ali (Alastair) Mitchell and Michelle Robson. Its official site presents European pre-seed/seed and global Series B+ strategies. Axo Neurotech and MintNeuro are directly listed current early-stage investments, making this a verified neurotechnology investor at the firm-claim level. Flow Engineering has independently supported recent round participation. Do not merge this firm with Oliver Cameron's AI company Odyssey or automatically assign founders' earlier investments to the new funds. [Official site](https://odyssey.ventures/ ) (undated; accessed 2026-10-06).
## Starting evidence: Adex and NFX Signal
Read the saved exact-ID snapshot `data/research/_sources/OdysseyVentures.adex.json`, retrieved 2026-10-06. It describes the transatlantic seed/growth firm, gives no check-size figures, and lists 17 investment entries with unknown dates/amounts: Axo Neurotech, Flow Engineering, Potential Sciences, Viridi, Handshake, Pleo, Peakon, AnyDesk, Beamery, Heart Aerospace, Aether Fuels, Oden Technologies, Permutive, Amogy, Standard AI, Untap Health and Nodals AI. Its source is largely the old portfolio page, including a section called “Select other investments,” an attribution warning rather than a confirmed new-firm transaction list. The record also contains Oliver Cameron CEO/unknown roles alongside Mitchell, Robson and Mark Charkin.
[NFX firm page](https://signal.nfx.com/firms/odyssey-ventures ) was directly read but yielded only the name and an empty team area. The [Oliver Cameron Signal profile](https://signal.nfx.com/investors/oliver-cameron ) was accessible through search-index text: angel investor, CEO at Odyssey, “Current Investing Position: Odyssey Ventures,” $10,000–$500,000 investment range and $100,000 sweet spot, with investments such as Extropic AI and Sereact. These figures and transactions describe Cameron's profile and are **not evidence for Mitchell/Robson's firm**. Signal's association is ambiguous; no independent connection to the London fund was established. All Signal access on 2026-10-06; profiles undated.
Cameron's separate company says he and Jeff founded Odyssey in 2023 and announced a $310 million Series B on 2026-06-17. This is company financing, not this firm's fund size. [Company announcement](https://odyssey.systems/our-series-b ). Review the Adex roles and Signal association before treating them as valid.
## Fund size, vintages and closing status
| Vehicle / metric | Latest dated evidence found | Interpretation |
| --- | --- | --- |
| Odyssey Discovery I | British Business Bank, 2026-07-23: **US$50 million** pre-seed/seed fund, **50% closed**, aiming for final close after summer | Treat $50m as announced intended full fund size; do not record a verified $50m final close. No later final-close confirmation found in the checked sources. |
| British Business Bank Regional Angels Programme | Same announcement: **£10 million commitment to invest alongside** the early-stage fund | Separate co-investment commitment; not automatically part of fund commitments or deployable closed fund total. |
| Total firm AUM | Same announcement: **US$87 million** across Access (AI global growth) and Discovery (AI/deep-tech UK-to-US early stage) | Combined AUM, not one fund. No supported vehicle-by-vehicle decomposition; do not subtract the fund target from AUM to infer Access size. |
| 2025 launch reporting | 2025-10-15 Tech Funding News reports **US$75 million** debut fund; 2025-11-02 founder interview introduces a $75m debut fund | Historical reported figure conflicts with the newer $50m Discovery description. Target, vehicle perimeter or fundraising plans may have changed, but sources do not resolve it. Not verified as final closed commitments. |
| Access growth strategy | Official site confirms global growth platform; PEI publicly lists “Odyssey Ventures Access (Growth) I” in market | Numerical target/close/vintage unverified. PEI's sizes are paywalled. |
Primary fund evidence: [British Business Bank announcement, 2026-07-23](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-commits-ps10m-odyssey-ventures-back-uks-boldest-ai-and-deeptech-founders ). Historical context: [Tech Funding News, 2025-10-15](https://techfundingnews.com/odyssey-ventures-75m-fund-bridges-europe-us-startup-valuation-gap/ ); [Ali Mitchell interview, 2025-11-02](https://sundaycet.com/2025/11/02/ali-mitchell-odyssey-ventures-the-reality-is-that-most-european-vcs-are-generalists-run-by-non-founders/ ); [PEI profile](https://www.privateequityinternational.com/institution-profiles/odyssey-ventures.html ) (undated, accessed 2026-10-06; Fund I open date September 2025, amounts inaccessible). All amounts preserve original currency. No verified firm check range found.
## Stages and mandate
The official homepage supports initial pre-seed/seed backing for European founders and Series B+ global growth. The Bank's July 2026 Discovery description is narrower: UK founders in AI/deep tech. Retain this geographic difference between broad website platform and specific vehicle. A Series A transaction also exists historically; this does not justify describing Discovery as primarily Series A. [Official homepage](https://odyssey.ventures/ ); [Bank release](https://www.british-business-bank.co.uk/news-and-events/news/british-business-bank-commits-ps10m-odyssey-ventures-back-uks-boldest-ai-and-deeptech-founders ).
## Named deep-tech investments
| Company | Technical rationale and evidence | Firm attribution, stage/date and limitations |
| --- | --- | --- |
| **Axo Neurotech** | Biohybrid neural interfaces using living cells/material science to connect electronics and the nervous system; direct neurotech and deep tech. King's College describes patents and pre-seed fundraising. | Current official homepage explicitly lists early-stage Axo. Firm investment amount/date undisclosed; King's page names other current investors, not Odyssey, so independent equity-round attribution remains unverified. See dedicated neurotech section. |
| **MintNeuro** | Specialized low-power semiconductors for neural implant sensing/stimulation. Direct neurotech and semiconductor deep tech. | [Odyssey company page](https://odyssey.ventures/companies/mintneuro ) explicitly says current early-stage fund/invested early-stage and names Empirical Ventures as co-investor; date, amount and exact round undisclosed. See neurotech section. |
| **Viridi / ViridiCO2** | Catalysts using captured carbon as chemical feedstock; technical chemistry spinout, not ordinary software. [Investee about page](https://viridico2.co.uk/about-us/ ) supports the technology and Southampton origin. | [Odyssey portfolio detail](https://odyssey.ventures/companies/viridi ) explicitly lists current/invested early-stage with EQT Ventures and Possible Ventures. However, [Odyssey news](https://odyssey.ventures/news ) claims “we led” its seed; investee says EQT led the £3m seed, and [EQT portfolio](https://eqtgroup.com/about/current-portfolio/viridico2 ) dates EQT entry to 2023. Odyssey was founded 2025. Do not attribute the 2023 £3m seed lead to Odyssey without clarifying earlier partner/vehicle history. Current firm claim supported; specific round/date unresolved. |
| **Flow Engineering** | Agentic systems engineering joining CAD, requirements, simulation and testing for complex physical products. Deep-tech enabling software; no claim that Flow manufactures customers' hardware. | [Company release, 2026-09-30](https://www.flowengineering.com/blog/series-b-press-release ) confirms **$50m Series B**, **$750m valuation**, co-led by Valor/Atreides and participation by Odyssey. [Firm detail](https://odyssey.ventures/companies/flow-engineering ) identifies current Global Growth and invested Early-Stage/Global Growth. [Firm news](https://odyssey.ventures/news ) also claims participation in **$23m Series A, 2025-10-14**, and earlier seed leadership; its earliest involvement could include Mitchell's earlier career. The Series B is independently attributed; individual Odyssey check unknown. | SHOW MORE
team@apexlogos.ai · 23 days ago
MATCH 
Roelof Botha
Flow Engineering$23M · 2025-10-14
MintNeuro
Nodals AI
Standard AI
Heart Aerospace
Peakon
Pleo
Handshake
Axo Neurotech